|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We conclude that uPA gene amplification is not a major mechanism instigating uPA overexpression in breast cancer, and that overexpression is likely to be controlled by other mechanisms.
|
7695959 |
1995 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review focuses on uPA system, summarizes their biological effects, highlights the molecular mechanism and pathway, and discusses the role of uPA system in the prevention and treatment of human breast cancers.
|
23201006 |
2013 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcription-PCR analysis revealed that this demethylation of the uPA promoter is directly associated with induction of uPA mRNA expression, which is well known to be associated with poor prognosis in breast cancer patients.
|
15131040 |
2004 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Determination of uPA and PAI-1 concentrations in the breast cancer tissue extracts was performed using FEMTELLE® uPA/PAI-1 ELISA.
|
30646864 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
|
15150277 |
2004 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our laboratory recently showed that insulin-like growth factor-I (IGF-I) induces uPA protein and mRNA in the breast cancer cell line MDA-MB-231.
|
11245436 |
2001 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Using an ARE-gene microarray, novel targets of TTP regulation were identified, namely, urokinase plasminogen activator (uPA), uPA receptor and matrix metalloproteinase-1, all known to have prominent roles in breast cancer invasion and metastasis.
|
20498646 |
2010 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Urokinase-type plasminogen activator (uPA) has been validated as a predictive or prognostic biomarker protein, and mesupron is considered the first-in-class anticancer agent to inhibit uPA activity in human breast cancer.
|
28560500 |
2017 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, a full-length human HER-2/neu cDNA was introduced into five human breast cancer cell lines to define the effects of HER-2/neu overexpression on uPA and PAI-1 expression.
|
11489825 |
2001 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, the role(s) of OPN on AP-1-mediated uPA secretion and cell motility and the involvement of c-Src/epidermal growth factor receptor (EGFR) in these processes in breast cancer cells are not well defined.
|
14704150 |
2004 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
As a prognostic marker for breast cancer the information supplied by uPA is both independent of traditionally used factors and significant in the important subgroup of axillary-node patients.
|
12023852 |
2002 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Genetic deficiency of uPA leads to a significant reduction in metastases in the murine transgenic MMTV-PyMT breast cancer model, demonstrating a causal role for uPA in cancer dissemination.
|
26040548 |
2015 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
|
10766865 |
2000 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Stromal cells also contribute to breast cancer growth and metastasis through the production of extracellular matrix (ECM) modifiers such as urokinase type plasminogen activator (uPA), its receptor (uPAR), its inhibitors (PAI-1 and PAI-2), matrix metalloproteinases (MMPs), and growth factors, including the fibroblast and insulin-like growth factors (FGF's and IGF's).
|
12574821 |
2003 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Urokinase type plasminogen activator (uPA) is a serine protease that is involved in cancer progression, especially invasion and metastasis of breast cancer.
|
25377085 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
|
29107218 |
2018 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, we characterized adipocytes from breast and omental tissues for PAI-1 and uPA, and the influence of adipocytes on breast cancer cell motility.
|
22445926 |
2012 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
When using uPA- and PAI-1 levels as prognostic and predictive factors in breast cancer the quantity of tumor stroma in the tumor tissue specimen is not relevant for the assessment of the patients' outcome.
|
19475533 |
2009 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
|
19701247 |
2009 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
In the present study we assessed uPA-R distribution in formalin-fixed, paraffin-embedded breast cancer specimens (n=50) and benign lesions (n=10) by immunohistochemistry employing a newly developed polyclonal chicken antibody to uPA-R (pAb HU277) in parallel with established monoclonal antibody (mAb) 3936 to uPA-R.
|
9681686 |
1998 |